COVID-19 | BioTuesdays

This Week's Feature

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

aTyr Pharma (NASDAQ:LIFE) expects to report before the end of 2020 results of a Phase 2 study with its ATYR1923 drug candidate in COVID-19-related severe respiratory complications. It also has a data readout planned in...

September 29, 2020

Developments

Hepion CRV431 shows positive activity against SARS-CoV-2 in NIAID study

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431 demonstrated positive activity against SARS-CoV-2 in a preclinical study conducted at the National Institute of Allergy and Infectious Diseases (NIAID). Conducted under...

September 17, 2020

Features

BioCardia developing autologous and allogenic cardiovascular cell therapies

BioCardia (NASDAQ:BCDA) is developing two late-stage clinical autologous cell therapies, known as CardiAMP, for ischemic heart failure and chronic myocardial ischemia, a neurokinin 1 receptor positive (NK1R+) allogenic...

September 15, 2020

Developments

iBio featured on ABC affiliate

KXXV, an ABC affiliate in Bryan, Texas, published an article on iBio’s (NYSE AMERICAN:IBIO) two COVID-19 vaccine candidates. The company recently reported that it has selected IBIO-201 as its leading candidate for...

September 11, 2020

Developments

Hepion CRV431 featured on The Bio Report podcast

The Bio Report podcast featured Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431 for the treatment of non-alcoholic steatohepatitis (NASH), and potentially, COVID-19. “We’ve kicked off our Phase 2 trial in NASH...

September 11, 2020

Developments

iBio selects IBIO-201 as its leading COVID-19 vaccine candidate

iBio (NYSE AMERICAN:IBIO) selected IBIO-201 as its leading candidate for the prevention of SARS-CoV-2 infection. iBio previously reported that both of its COVID-19 vaccine candidates, IBIO-200 and IBIO-201, in...

September 9, 2020

Developments

iBio and Planet Biotechnology in pact to develop COVID-19 therapeutic

iBio (NYSE AMERICAN:IBIO) entered into an exclusive worldwide license agreement with Planet Biotechnology for the development of Planet’s COVID-19 therapeutic candidate, ACE2-Fc. ACE2-Fc is a recombinant protein...

August 28, 2020

Developments

Vanda Pharma reports interim results from Phase 3 COVID-19 trial

Vanda Pharmaceuticals (NASDAQ:VNDA) reported interim results from its Phase 3 trial assessing tradipitant for the treatment of COVID-19 pneumonia. The data are based on the first 60 patients enrolled in the study, who...

August 18, 2020

Developments

Omeros reports positive results from COVID-19-associated ARDS trial

Omeros (NASDAQ:OMER) reported positive results from a study evaluating narsoplimab for the treatment of COVID-19-associated acute respiratory distress syndrome (ARDS). Narsoplimab is a human monoclonal antibody that is...

August 10, 2020

Developments

IBIO-201 demonstrates ability to elicit anti-SARS-CoV-2 immune response in preclinical studies

iBio (NYSE AMERICAN:IBIO) reported initial results from preclinical studies of IBIO-201, one of its two COVID-19 vaccine candidates. IBIO-201 is a subunit vaccine that combines antigens derived from the SARS-CoV-2 spike...

August 10, 2020

Developments

The Hill’s coronavirus report features iBio COVID-19 vaccine candidates and FastPharming System

iBio’s (NYSE AMERICAN:IBIO) two COVID-19 vaccine candidates and FastPharming manufacturing system were featured on The Hill’s coronavirus report on July 30. The company is developing IBIO-200 and IBIO-201, virus-like...

July 30, 2020

Developments

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

The first patients have been enrolled in an investigator-sponsored Phase 2 study evaluating Immunic Therapeutics‘ (NASDAQ:IMUX) IMU-838 for the treatment of COVID-19. IMU-838 is a selective immune modulator that...

July 27, 2020

Developments

Cerecor enrolls first patient in COVID-19 trial

Cerecor (NASDAQ:CERC) enrolled the first patient in its a proof-of-concept trial evaluating CERC-002 in patients with COVID-19 cytokine storm-induced acute respiratory distress syndrome (ARDS). CERC-002 is a...

July 21, 2020

Developments

PhaseBio doses first COVID-19 patient in Phase 2 trial

PhaseBio Pharmaceuticals (NASDAQ:PHAS) dosed the first patient in its potentially pivotal Phase 2 trial evaluating PB1046 for the treatment of high-risk, hospitalized COVID-19 patients. PB1046 is a long-acting analog of...

July 17, 2020

Markets

HCW ups electroCore PT to $2.50 from $1.50

H.C. Wainwright raised its price target for electroCore (NASDAQ:ECOR) to $2.50 from $1.50, citing the FDA’s emergency use authorization of gammaCore, the company’s lead product, to treat COVID-19 patients. The stock...

July 15, 2020

Developments

Rigel Pharma fostamatinib being evaluated in COVID-19 pneumonia trial

Rigel Pharmaceuticals’ (NASDAQ:RIGL) fostamatinib is being evaluated in an investigator-sponsored study for the treatment of COVID-19 pneumonia. Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, is approved...

July 14, 2020

Developments

Akebia vadadustat being evaluated for COVID-19-related acute respiratory distress syndrome

Akebia Therapeutics’ (NASDAQ:AKBA) vadadustat is being evaluated in an investigator-sponsored study as a potential therapy to prevent and lessen the severity of COVID-19-related acute respiratory distress syndrome...

July 14, 2020

Developments

BioSig subsidiary begins enrollment in Phase 2 COVID-19 trial

ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies (NASDAQ: BSGM), began enrolling patients in its Phase 2 clinical trial of merimepodib for the treatment of COVID-19. Merimepodib is an orally...

July 13, 2020

Developments

Bellerophon treats first COVID-19 patient in Phase 3 INOpulse study

Bellerophon Therapeutics (NASDAQ:BLPH) treated the first patient in its Phase 3 study evaluating INOpulse, a pulsed nitric oxide system, for the treatment of COVID-19. The study will enroll up to 500 patients requiring...

July 13, 2020

Developments

FDA authorizes emergency use of electroCore’s vagus nerve stimulation in COVID-19 patients

The FDA has issued an emergency use authorization for electroCore’s (NASDAQ:ECOR) gammaCore Sapphire CV non-invasive vagus nerve stimulation (nVNS) to treat adult patients with known or suspected COVID-19. The FDA has...

July 13, 2020

Developments

Hepion Pharma posts preclinical data supporting two-pronged approach treating COVID-19 with CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that its anti-fibrotic drug candidate, CRV431, was efficacious in two distinct preclinical research models related to COVID-19 disease. CRV431 demonstrated strong anti...

July 7, 2020

Developments

Luminal BioSciences provides guidance on milestones; begins collecting plasma from COVID-19 recovered donors

Liminal BioSciences (NASDAQ, TSX:LMNL) provided a guidance update on the timing of certain expected key milestones for 2020. The company withdrew guidance in May because of the COVID-19 pandemic. In a statement, Kenneth...

July 1, 2020

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

Hepion CRV431 shows positive activity against SARS-CoV-2 in NIAID study

BioCardia developing autologous and allogenic cardiovascular cell therapies

iBio featured on ABC affiliate

Hepion CRV431 featured on The Bio Report podcast

iBio selects IBIO-201 as its leading COVID-19 vaccine candidate

iBio and Planet Biotechnology in pact to develop COVID-19 therapeutic

Vanda Pharma reports interim results from Phase 3 COVID-19 trial

Omeros reports positive results from COVID-19-associated ARDS trial

IBIO-201 demonstrates ability to elicit anti-SARS-CoV-2 immune response in preclinical studies

The Hill’s coronavirus report features iBio COVID-19 vaccine candidates and FastPharming System

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

Cerecor enrolls first patient in COVID-19 trial

PhaseBio doses first COVID-19 patient in Phase 2 trial

HCW ups electroCore PT to $2.50 from $1.50

Rigel Pharma fostamatinib being evaluated in COVID-19 pneumonia trial

Akebia vadadustat being evaluated for COVID-19-related acute respiratory distress syndrome

BioSig subsidiary begins enrollment in Phase 2 COVID-19 trial

Bellerophon treats first COVID-19 patient in Phase 3 INOpulse study

FDA authorizes emergency use of electroCore’s vagus nerve stimulation in COVID-19 patients

Hepion Pharma posts preclinical data supporting two-pronged approach treating COVID-19 with CRV431

Luminal BioSciences provides guidance on milestones; begins collecting plasma from COVID-19 recovered donors

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter